Oklahoma Healthcare Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

April 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Press releases published on April 21, 2026

Apr. 21, 2026

Triple Green Farms CBD Gummies Claims Evaluated: The Best CBD Gummy Formula on the Market Under Investigation

GlobeNewswire

Apr. 21, 2026

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

GlobeNewswire

Apr. 21, 2026

RNK Health NAD+ Longevity Therapy Claims Evaluated: The Clinician-Guided NAD Injections & Medication Protocol

GlobeNewswire

Apr. 21, 2026

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

GlobeNewswire

Apr. 21, 2026

Panakeia Unveils Landmark Metabolic and Pathway Activation Data in Cancers at AACR 2026

GlobeNewswire

Apr. 21, 2026

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

GlobeNewswire

Apr. 21, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

GlobeNewswire

Apr. 21, 2026

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

GlobeNewswire

Apr. 21, 2026

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire

Apr. 21, 2026

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

GlobeNewswire

Apr. 21, 2026

Intuitive Announces First Quarter Earnings

GlobeNewswire

Apr. 21, 2026

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

GlobeNewswire

Apr. 21, 2026

STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026

GlobeNewswire

Apr. 21, 2026

Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire

Apr. 21, 2026

Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

GlobeNewswire

Apr. 21, 2026

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

GlobeNewswire

Apr. 21, 2026

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

Apr. 21, 2026

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

GlobeNewswire

Apr. 21, 2026

Oculis Publishes Invitation to the Annual General Meeting

GlobeNewswire

Apr. 21, 2026

TELA Bio to Announce First Quarter 2026 Financial Results

GlobeNewswire